Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.53 |
| ▸ | CA2 | P00918 | 5/20 | 0.53 |
| ▸ | ACHE | P22303 | 5/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 3/20 | 0.44 |
| ▸ | DRD3 | P35462 | 3/20 | 0.44 |
| ▸ | DRD4 | P21917 | 2/20 | 0.44 |
| ▸ | FAAH | O00519 | 7/20 | 0.44 |
| ▸ | SOD1 | P00441 | 1/20 | 0.43 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL346094 | 0.94 | CA1 (0.53) | CA1CA2ACHEOPRK1DRD2 | |
| SCHEMBL2464708 | 0.87 | KMT2A (0.48) | CA1CA2ACHEOPRK1DRD2 | |
| SCHEMBL24214577 | 0.87 | FAAH (0.43) | CA1CA2ACHEFAAH | |
| SCHEMBL5889332 | 0.85 | FAAH (0.44) | CA1CA2ACHEFAAH | |
| SCHEMBL9218363 | 0.85 | FAAH (0.44) | CA1CA2ACHEFAAH | |
| SCHEMBL629772 | 0.84 | OPRK1 (0.48) | CA1CA2ACHEOPRK1DRD2 | |
| SCHEMBL15431081 | 0.84 | FAAH (0.43) | CA1CA2ACHEFAAH | |
| SCHEMBL17443397 | 0.84 | HTR1D (0.48) | CA1CA2ACHEFAAH | |
| SCHEMBL8066286 | 0.84 | CA1 (0.59) | CA1CA2ACHEDRD2DRD3 | |
| SCHEMBL8076218 | 0.84 | CA1 (0.59) | CA1CA2ACHEDRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10894040-B2 | S1P modulating agents | BIOGEN MA INC. (US) | 2021-01-19 | — | — | US | disclosed |
| US-10894040-B2 | S1P modulating agents | BIOGEN MA INC. (US) | 2021-01-19 | — | — | US | disclosed |
| EP-3660010-A1 | S1P MODULATING AGENTS | Biogen MA Inc. (US) | 2020-06-03 | — | — | EP | disclosed |
| EP-3660010-A1 | S1P MODULATING AGENTS | Biogen MA Inc. (US) | 2020-06-03 | — | — | EP | disclosed |
| US-20200038385-A1 | S1P MODULATING AGENTS | BIOGEN IDEC MA INC. | 2020-02-06 | — | — | US | disclosed |
| US-20200038385-A1 | S1P MODULATING AGENTS | BIOGEN IDEC MA INC. | 2020-02-06 | — | — | US | disclosed |
| EP-3150590-B1 | S1P MODULATING AGENTS | BIOGEN MA INC (US) | 2019-10-16 | — | — | EP | disclosed |
| EP-3150590-B1 | S1P MODULATING AGENTS | BIOGEN MA INC (US) | 2019-10-16 | — | — | EP | disclosed |
| US-10406144-B2 | SIP modulating agents | BIOGEN MA INC. (US) | 2019-09-10 | — | — | US | disclosed |
| US-20180369215-A1 | S1P MODULATING AGENTS | BIOGEN IDEC MA INC. | 2018-12-27 | — | — | US | disclosed |
| EP-2672823-A1 | S1P MODULATING AGENTS | Biogen Idec MA Inc. (US) | 2013-12-18 | — | — | EP | disclosed |
| EP-2670245-A1 | ALPHA-KETOHETEROCYCLES AND METHODS OF MAKING AND USING | The Scripps Research Institute (US) | 2013-12-11 | — | — | EP | disclosed |
| WO-2012109108-A1 | S1P MODULATING AGENTS | BIOGEN IDEC MA INC. (US) | 2012-08-16 | — | — | WO | disclosed |
| WO-2012109108-A1 | S1P MODULATING AGENTS | BIOGEN IDEC MA INC. (US) | 2012-08-16 | — | — | WO | disclosed |
| WO-2012106569-A1 | ALPHA-KETOHETEROCYCLES AND METHODS OF MAKING AND USING | BOGER DALE L (US) | 2012-08-09 | — | — | WO | disclosed |
| WO-2012012320-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENIUM PHARMACEUTICALS, INC. (US) | 2012-01-26 | — | — | WO | disclosed |
| WO-2012012320-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENIUM PHARMACEUTICALS, INC. (US) | 2012-01-26 | — | — | WO | disclosed |
| US-20120015942-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120015942-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120015942-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200038385-A1 | S1P MODULATING AGENTS | S1PR2, S1PR1, S1PR3 | CA1 4113/4885CA2 3671/4885ACHE 4567/4885 |
| US-20120015942-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC2 | CA1 400/4885CA2 413/4885ACHE 3602/4885 |
| US-10406144-B2 | SIP modulating agents | S1PR2, S1PR1, S1PR3 | CA1 2076/4885CA2 1935/4885ACHE 4487/4885 |
| US-10894040-B2 | S1P modulating agents | S1PR2, S1PR1, S1PR3 | CA1 4115/4885CA2 2230/4885ACHE 4328/4885 |
| US-20180369215-A1 | S1P MODULATING AGENTS | S1PR2, S1PR1, S1PR3 | CA1 4113/4885CA2 3671/4885ACHE 4567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.